Search
Clove oil
go.drugbank.com/drugs/DB11338ApprovedNutraceuticalClove is native of Indonesia but is now cultured in several parts of the world, including Brazil in the state of _Bahia_. … Clove oil is obtained by extraction from the dried flower buds of the clove plant. Traditionally, it has been used as a flavouring spice in foods, or as a fragrance.
Mixtures: DİŞİNOL 2 G + 0,5 G + 3,5 G/10 ML ÇÖZELTİ, RELISPRAY ™ PAIN RELIEF SPRAYEchinacoside
go.drugbank.com/drugs/DB15488Investigational[A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,
Sulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Categories: combinations of sulfonamidesSynonyms: 4-Sulfanilamido-5,6-dimethoxypyrimidineDDP-225
go.drugbank.com/drugs/DB05642InvestigationalThe unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases. … Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system.
Categories: Heterocyclic Compounds, 1-RingElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesHomatropine
go.drugbank.com/drugs/DB11181ApprovedIt is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. … Homatropine is included in subtherapeutic amounts as homatropine methylbromide to discourage deliberate overdosage.
Products: HOMATRO 2%, Isopto Homatropine 2%Voxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Categories: Sex Hormones and Modulators of the Genital System, Cytochrome P-450 SubstratesRindopepimut
go.drugbank.com/drugs/DB05374InvestigationalRindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. … The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.
Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexProducts: ICLUSIG® 15 MG TABLETAS RECUBIERTAS